ASCO 2022 Conference Coverage


 

Lecture Summary - ASCO 2022 Phase 2 Study of Response-Guided Neoadjuvant Sacituzumab Govitecan (IMMU-132) in Localized TNBC: Results From the NeoSTAR Trial

27 views
June 21, 2022
0 Comments
Login to view comments. Click here to Login
Breast